Search results
Showing 256 to 270 of 1079 results for infections
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done? Any explanatory...
This indicator covers the percentage of children who reached 18 months old in the preceding 12 months, who have received 2 primary doses and 1 booster dose of a meningitis B vaccine before the age of 18 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
This indicator the percentage of babies who reached 8 months old in the preceding 12 months, who have received 2 doses of a meningitis B vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM207
This indicator covers the percentage of babies who reached 24 weeks old in the preceding 12 months, who have received 2 doses of rotavirus vaccine before the age of 24 weeks. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM206
This indicator covers the percentage of children who reached 5 years old in the preceding 12 months, who have received 1 dose of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM200
This indicator covers the percentage of children who have reached 5 years old in the preceding 12 months, who have received a reinforcing dose of DTaP/IPV and at least 2 doses of MMR between the ages of 1 and 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM199
This indicator covers the percentage of children who reached 18 months old in the preceding 12 months, who have received at least 1 dose of MMR between the ages of 12 and 18 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM198
This indicator covers the percentage of babies who reached 8 months old in the preceding 12 months, who have received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before the age of 8 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM197
This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.
View quality statements for QS63Show all sections
Sections for QS63
- Quality statements
- Quality statement 1: Assessing recent changes that may indicate delirium
- Quality statement 2: Interventions to prevent delirium
- Quality statement 3: Use of antipsychotic medication for people who are distressed
- Quality statement 4: Information and support
- Quality statement 5: Communication of diagnosis to GPs
- Update information
- About this quality standard
Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)
Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Adalimumab for treating moderate to severe plaque psoriasis (TA146)
Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults....
View recommendations for HTE28Show all sections